In terms of therapeutic strategies, IL-18 antagonists have demonstrated the potential to inhibit tumor growth in experimental models, indicating that modulating IL-18 levels or its signaling pathways may offer novel approaches to enhance treatment outcomes for glioma patients (da Silva et al., 2020; Ji et al., 2024). This evidence concerns the gene IL18 and glioma.